Strategic partnerships MS Pharma has active collaboration initiatives with academic institutions and international biosimilar developers, including memoranda with Jordan University of Science and Technology and partnerships with Hetero Group, Polpharma Biologics, Kashiv BioSciences, signaling strong openness to co-development, technology transfer, and localized manufacturing opportunities.

Biosimilar expansion The company is aggressively expanding in biosimilars across oncology, immunology and hematology through licensing, localization agreements, and regional leadership in MENA, presenting multiple entry points for supply, contract manufacturing, and regional distribution partnerships.

Strategic minority funding Recent minority equity investment from Olayan Financing Company indicates investor confidence and potential for scaled capital to support manufacturing capacity, R&D, and commercial expansion in the Gulf region and broader MENA markets.

Regional growth engine Positioned as a leading regional pharma player with a strong MEA growth trajectory and a sizable workforce, MS Pharma presents opportunities for channel partnerships, local market access programs, and digital transformation collaborations leveraging its SAP and tech stack.

Market readiness With a revenue range around half a billion to one billion USD and a track record of international partnerships, there is potential to pursue contract manufacturing, distribution agreements, and co-marketing deals to scale biosimilar portfolios and specialty therapies in the MENA region.